Sunshine Biopharma (SBFM) Current Assets (2010 - 2026)

Sunshine Biopharma has reported Current Assets for 16 years, with the latest figure at $24.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 1.23% year-over-year to $24.8 million; the trailing twelve-month figure through Mar 2026 stood at $24.8 million (up 1.23% YoY), and the FY2025 full-year result was $26.9 million, up 3.42% from the prior year.
• Current Assets for Q1 2026 stood at $24.8 million, down from $26.9 million in the prior quarter.
• The five-year high for Current Assets was $42.0 million in Q2 2022, with the low at $13.4 million in Q1 2022.
• Historically, Current Assets has averaged $27.3 million across 5 years, with a median of $26.0 million in 2024.
• Annual changes were most pronounced in 2022 — Current Assets jumped 2228.1% — and 2023, when it tumbled 37.84%.
• Sunshine Biopharma's Current Assets stood at $27.3 million in 2022, then decreased by 8.87% to $24.9 million in 2023, then increased by 4.32% to $26.0 million in 2024, then climbed by 3.42% to $26.9 million in 2025, then retreated by 7.71% to $24.8 million in 2026.
• The last three Current Assets figures came in at $24.8 million (Q1 2026), $26.9 million (Q4 2025), and $28.0 million (Q3 2025), per Business Quant data.